Targeted therapy of atopic dermatitis in children
A.S. Botkina, M.I. Dubrovskaya, O.O. Khandamirova
Pirogov Russian National Research Medical University, Moscow, Russia
Atopic dermatitis (AD) is one of the most common dermatoses affecting up to 20% of children and 10% of the adult population of the planet. Recently, there has been a significant increase in the incidence and an increase in severe, treatment-resistant forms of the dis- ease, which inevitably leads to polypharmacy. According to modern concepts, the immune dysregulation manifested, in particular, by hyperproduction of interleukin-4 (IL-4) and IL-13, plays a central role in the pathogenesis of dermatosis. The achievements of modern medical science have made it possible to use targeted therapy for the treatment of AD and to have a selective effect on the pathogen- esis of the disease, suppressing or significantly reducing allergic inflammation in the skin. Dupilumab, the first and only biologic drug approved by the FDA for the treatment of moderate to severe AD in children, targets the signaling of key cytokines, IL-4 and IL-13. The use of genetic engineering technologies in the treatment of AD was a breakthrough, allowing not only to mask the symptoms of the disease, but also to change the its course.
About the Autors
Corresponding author: Aleksandra S. Botkina, Cand. Sci. (Med.), Associate Professor at the, Department of Hospital Pediatrics n.a. Acad. V.A. Tabolin, Faculty of Pediatrics, Pirogov Russian National Research Medical University, Moscow, Russia; email@example.com